Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

979 - CD200 and indoleamine 2,3-dioxygenase-1 (IDO-1) overexpresion in relapsed acute myeloid leukemia patients


11 Sep 2017


Poster display session




Ali Memarian


Annals of Oncology (2017) 28 (suppl_5): v1-v21. 10.1093/annonc/mdx361


A. Memarian1, S. Abdolmaleki2, M. Mirahmadian2, M. Jeddi-Tehrani3

Author affiliations

  • 1 Stem Cell Research Center, Golestan University of Medical Sciences, 49189-36316 - Gorgan/IR
  • 2 Department Of Immunology, Tehran University of Medical Sciences, Tehran/IR
  • 3 Monoclonal Antibody Research Center, Avicenna Research Institute, Tehran/IR


Abstract 979


Immunosuppression is one of the major causes of AML pathogenesis and progression. CD200 and IDO are immunoregulatory factors which overexpressed in some solid tumors and hematological malignancies. Distinct researches have shown CD200 and IDO expression is associated with AML progression. In the current study, we simultaneously examined the expression of these molecules, as the two important factors including in immunosuppression, in the newly diagnosed and relapse AML patients to investigate their correlation with each other.


48 PBMC samples of newly diagnosed and relapse AML patients were tested and also 32 normal subjects were employed as control. CD200 expression level was examined on cells by Flow cytometry and quantitative real time RT-PCR was used to determine the IDO-1 gene expression. Finally, data were analyzed statistically.


Data showed that CD200 and IDO-1 overexpressed especially in relapsed patients. Comparison between FAB AML subgroups demonstrated no statistical differences in the case of CD200 level but expression of IDO-1 was slightly increased only in M4 subgroup in comparison to M3. Correlation analyses showed strong association between expression of CD200 and IDO-1 in all patients particularly in relapsed AML, whereas no significant correlation was found in normal subjects.


According to the role and overexpression of CD200 and IDO-1 in AML patients and also their two-way correlation with T-regs in disease induction and progression, simultaneous assessment of these parameters are so valuable for more exact prognosis detection. Also inhibition of all these immunoregulatory pathways could be so useful for immunotherapy outcome, especially in relapsed AML.

Clinical trial identification

Legal entity responsible for the study

Tehran University of Medical Sciences




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.